Alithea Genomics, a pioneering biotech company based in Switzerland and the USA specializing in scalable RNA sequencing solutions, today announced the launch of MERCURIUS™ Total DRUG-seq, a new extraction-free, full-length transcriptome profiling library preparation kit designed to push the boundaries of high-throughput drug screens, toxicology screens and target validation by enabling the creation of large-scale data generation for machine learning and AI.
Building on the success of its MERCURIUS™ 3’ DRUG-seq, MERCURIUS™ Total DRUG-seq captures the complete transcriptome—including lncRNAs and other non-coding RNAs—with greater sensitivity, full-length coverage, and unprecedented multiplexing capacity, enabling researchers to screen over 50,000 samples with confidence.
The kit is available in 96-well (1,000–25,000 cells) and 384-well (500–10,000 cells) formats and features a streamlined, extraction-free protocol that delivers faster turnaround, lower input requirements, and expanded insights, without sacrificing scalability or reproducibility.
